ASH 2014: Targeted therapies in a crowded cancer field
This article was originally published in Scrip
Targeted therapies for hematologic malignancies showed a wide range of response rates when abstracts for presentations during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition were released on 6 November.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.